Welcome to our dedicated page for Medicenna Therapeutics news (Ticker: MDNAF), a resource for investors and traders seeking the latest updates and insights on Medicenna Therapeutics stock.
Medicenna Therapeutics Corp. (MDNAF) is a clinical-stage immunotherapy company whose news flow is closely tied to the progress of its Superkine pipeline. Company updates consistently highlight advances in MDNA11, a long-acting IL-2 Superkine in the Phase 1/2 ABILITY-1 trial for advanced solid tumors, as well as developments in MDNA113, a tumor-anchored and conditionally activated PD-1 x IL-2 bifunctional Superkine, and bizaxofusp (MDNA55), an IL-4 Empowered Superkine for recurrent glioblastoma.
On this page, readers can follow MDNAF news related to clinical data readouts, new trial announcements and corporate milestones. Recent releases describe updated MDNA11 results in monotherapy and in combination with pembrolizumab, including activity in checkpoint inhibitor-resistant melanoma, MSS endometrial cancer, MSI-H and TMB-H tumors, as well as plans to complete enrollment in ABILITY-1 and prepare for potential registrational studies. News also covers the NEO-CYT neoadjuvant trial in high-risk, surgically resectable Stage III melanoma, sponsored by Fondazione Melanoma Onlus, which will evaluate MDNA11 in combination with nivolumab with or without ipilimumab.
Investors and clinicians can also track preclinical and non-human primate updates for MDNA113, including safety and pharmacodynamic findings that Medicenna reports as supporting its advancement toward first-in-human trials. Additional news items address partnering efforts and data presentations for bizaxofusp in recurrent glioblastoma, patent issuances protecting IL-2 and IL-4 Superkine assets, and participation in scientific and investor conferences.
By reviewing the MDNAF news feed, users can see how Medicenna communicates new clinical results, outlines expected milestones, and provides context on the scientific rationale behind its Superkine programs, while also including standard cautions about the risks and uncertainties inherent in drug development.
Medicenna Therapeutics announced that Dr. Fahar Merchant, its President and CEO, will present at the Bloom Burton & Co. Healthcare Investor Conference on April 20, 2021, at 10:00 AM ET. The presentation will provide an overview of the company's immuno-oncology developments, including its promising MDNA11 and MDNA55 assets, focused on cancer treatment. A live webcast will be accessible here. A replay will be available post-event on Medicenna's website.
Medicenna Therapeutics Corp. (NASDAQ: MDNA; TSX: MDNA) announced promising preclinical data for MDNA19-MDNA413, a dual-specific cytokine developed from their BiSKITs™ platform, presented at the AACR Annual Meeting. This innovative therapy selectively activates anti-cancer immune cells while inhibiting pro-tumoral macrophage polarization. Key findings highlighted a 209-fold and 90-fold enhancement in CD8/Treg and NK/Treg ratios, respectively, and effective suppression of IL-13 induced M2a macrophage polarization. Medicenna plans to advance its development and regulatory submissions for MDNA11, another promising superkine therapy.
Medicenna Therapeutics Corp. (NASDAQ: MDNA, TSX: MDNA) announced the presentation of an abstract during the AACR Annual Meeting 2021 on April 10-15, highlighting early preclinical studies of a novel bispecific Superkine. The abstract, titled Modulation of Immune Responses to Cancer by Bi-specific IL-2/IL-13 Superkines, focuses on an innovative approach combining IL-2 super-agonist with IL-4/IL-13 super-antagonist. The full abstract is available on AACR's website and will be accessible on Medicenna's site post-conference.
Medicenna Therapeutics Corp. (NASDAQ: MDNA TSX: MDNA) announced that Dr. Fahar Merchant, CEO, will present at multiple investor conferences in March 2021. These include the H.C. Wainwright Global Life Sciences Conference, with a pre-recorded presentation available on-demand from March 9, and the Oppenheimer 31st Annual Healthcare Conference, featuring a live presentation on March 17. Additionally, Dr. Merchant will participate in a live panel discussion at the Maxim 2021 Emerging Growth Virtual Conference on the same day. Details for accessing the webcasts are available on Medicenna's Investor Relations website.
Medicenna Therapeutics Corp. (NASDAQ: MDNA; TSX: MDNA) announced that CEO Dr. Fahar Merchant will present a corporate overview at the 41st Annual Cowen Healthcare Conference on March 2, 2021, at 2:10 PM ET. Interested parties can access a live webcast here. The presentation replay will be available on Medicenna's Investor Relations page. The company focuses on immunotherapy with assets like MDNA11 and MDNA55, targeting various cancers and has obtained Fast-Track designation from the FDA.
FAQ
What is the current stock price of Medicenna Therapeutics (MDNAF)?
What is the market cap of Medicenna Therapeutics (MDNAF)?
